T1G3 bladder cancer, bacillus Calmette-Guerin and radical cystectomy: continued debate.
作者信息
Brodie Andrew, McCauley Nadine, Cresswell Jo, Vasdev Nikhil
机构信息
Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK.
Department of Urology, James Cook University Hospital, Middlesbrough, UK.
出版信息
Transl Androl Urol. 2018 Dec;7(Suppl 6):S692-S695. doi: 10.21037/tau.2018.11.07.
Abstract
摘要
相似文献
1
T1G3 bladder cancer, bacillus Calmette-Guerin and radical cystectomy: continued debate.T1G3期膀胱癌、卡介苗与根治性膀胱切除术：持续的争论
Transl Androl Urol. 2018 Dec;7(Suppl 6):S692-S695. doi: 10.21037/tau.2018.11.07.
2
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.T1G3 非肌肉浸润性膀胱癌患者初始卡介苗治疗的预后因素和危险分组：2451 例患者回顾性多中心研究结果。
Eur Urol. 2015 Jan;67(1):74-82. doi: 10.1016/j.eururo.2014.06.040. Epub 2014 Jul 16.
3
Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer.高风险、高级别（T1G3）膀胱癌行即刻根治性膀胱切除术与膀胱内卡介苗治疗的成本效果分析。
Cancer. 2009 Dec 1;115(23):5450-9. doi: 10.1002/cncr.24634.
4
Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.卡介苗治疗非肌层浸润性膀胱癌患者癌症特异性生存预测模型的构建：一项多中心回顾性研究结果
Jpn J Clin Oncol. 2014 Nov;44(11):1101-8. doi: 10.1093/jjco/hyu119. Epub 2014 Aug 19.
5
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.高危Ta、T1期膀胱癌诱导使用卡介苗后的复发模式及预后
J Urol. 2007 May;177(5):1727-31. doi: 10.1016/j.juro.2007.01.031.
6
The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.卡介苗失败后根治性膀胱切除术的时机：结局比较和预后危险因素分析。
J Urol. 2016 Jun;195(6):1704-9. doi: 10.1016/j.juro.2016.01.087. Epub 2016 Jan 22.
7
Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.未接受卡介苗治疗的高级别非肌层浸润性膀胱癌患者的二次经尿道切除术及预后
Actas Urol Esp. 2014 Apr;38(3):164-71. doi: 10.1016/j.acuro.2014.01.001. Epub 2014 Mar 7.
8
An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.对新诊断的高级别 T1（以前为 T1G3）膀胱癌的治疗策略进行的最新批判性分析。
Eur Urol. 2010 Jan;57(1):60-70. doi: 10.1016/j.eururo.2009.08.024. Epub 2009 Sep 1.
9
Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer.肌联蛋白甲基化与 T1G3 膀胱癌患者的临床结局相关。
J Urol. 2010 Oct;184(4):1507-13. doi: 10.1016/j.juro.2010.05.085. Epub 2010 Aug 17.
10
[Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].[T1G3期膀胱癌的膀胱保留或初始膀胱切除术：哪些参数有助于治疗决策？]
Aktuelle Urol. 2008 Jan;39(1):58-61; discussion 62-3. doi: 10.1055/s-2007-980147.
引用本文的文献
1
Potential factors of specialists' willingness to write editorial and commentary: a retrospective study based on 5,091 invitations.专家撰写社论和评论意愿的潜在因素：一项基于5091份邀请的回顾性研究
Ann Transl Med. 2019 Dec;7(24):805. doi: 10.21037/atm.2019.12.75.
本文引用的文献
1
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.BCG 治疗后行根治性膀胱切除术的 T1G3 患者的肿瘤学结局预测因素。
World J Urol. 2018 Nov;36(11):1775-1781. doi: 10.1007/s00345-018-2450-0. Epub 2018 Aug 31.
2
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.根据卡介苗治疗的 T1G3 膀胱癌患者再次 TUR 时的分期，复发、进展和癌症特异性死亡率：并不像之前认为的那么糟糕。
World J Urol. 2018 Oct;36(10):1621-1627. doi: 10.1007/s00345-018-2299-2. Epub 2018 May 2.
3
Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.预测膀胱内卡介苗免疫治疗反应：我们做到了吗？系统评价。
Eur Urol. 2018 May;73(5):738-748. doi: 10.1016/j.eururo.2017.10.003. Epub 2017 Oct 18.
4
Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis.T1 非肌肉浸润性膀胱癌再次经尿道电切术的作用：系统评价和荟萃分析。
Eur Urol Focus. 2018 Jul;4(4):558-567. doi: 10.1016/j.euf.2016.12.011. Epub 2017 Jan 13.
5
Minimally Invasive Versus Open Approach for Cystectomy: Trends in the Utilization and Demographic or Clinical Predictors Using the National Cancer Database.微创与开放膀胱切除术方法：利用国家癌症数据库分析其应用趋势及人口统计学或临床预测因素
Urology. 2017 May;103:99-105. doi: 10.1016/j.urology.2017.02.018. Epub 2017 Feb 15.
6
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
7
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.肌肉浸润性膀胱癌的新辅助化疗：系统评价和两步荟萃分析
Oncologist. 2016 Jun;21(6):708-15. doi: 10.1634/theoncologist.2015-0440. Epub 2016 Apr 6.
8
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.EORTC 列线图和风险分组用于预测非肌肉浸润性 Ta-T1 期尿路上皮膀胱癌患者接受 1-3 年卡介苗维持治疗后的复发、进展、疾病特异性和总生存情况。
Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23.
9
Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.基于新型荧光原位杂交技术对卡介苗（BCG）治疗失败的定义，以促进膀胱内治疗临床试验的入组率。
BJU Int. 2016 May;117(5):754-60. doi: 10.1111/bju.13186. Epub 2015 Jul 3.
10
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.T1G3 非肌肉浸润性膀胱癌患者初始卡介苗治疗的预后因素和危险分组：2451 例患者回顾性多中心研究结果。
Eur Urol. 2015 Jan;67(1):74-82. doi: 10.1016/j.eururo.2014.06.040. Epub 2014 Jul 16.
Zotero 插件